![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » DicoverX Introduces KILR Assay Platform
DicoverX Introduces KILR Assay Platform
March 30, 2016
DiscoverX has launched its KILR Retroparticles platform to facilitate the development of cytotoxicity assays in most cell lines, the Fremont, Calif-based company announced Tuesday.
Versus traditional assays, the platform tackles the challenges of lack of throughput, sensitivity and specificity in measurement, the company says.
The assay features an “add-and-read protocol” for fast screening, lead optimization, characterization and QC lot release applications for protein and cellular therapies in cancer immunotherapy, according to company CEO Todd Nelson. — Anisa Jibrell
Upcoming Events
-
21Oct